GLP-1 medications are renowned for their ability to treat type 2 diabetes and aid weight loss. Now, there's a new benefit to ...

Discover how modern diabetes medications offer cardiovascular benefits, transforming diabetes care and improving outcomes worldwide.

WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA - a genetically validated target that provides a new approach for healthy, sustainable weight loss (fat loss with muscle preservation) ...

The Dow Jones rose Thursday after surprise weekly jobless claims. Nvidia partner Arm stock tumbled on earnings, while Roblox ...

Last Patient / Last Visit Completed Topline Data Readout Expected Later This Quarter CRANBURY, N.J., Feb. 6, 2025 /PRNewswire/ -- Palatin Technologies, Inc.

Slaughter and May has named a successor to managing partner Deborah Finkler. David Johnson is set to take the helm of the ...

WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA – a genetically validated target that provides a new ...

Response Pharmaceuticals, Inc., a clinical-stage company focused on weight management and metabolic health in high-risk populations, today announced the early completion of enrollment in a Phase 2 ...

TransCode Therapeutics, Inc. , the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that Cohort 3 of its Phase 1 clinical trial enrolled three ...

Direct-to-store model (delivering drugs directly to each retailer’s stores) of distributors are increasingly becoming more popular among retailers (represents 93% of sales in 2017, up from 74% in 2007 ...

After 2024, which saw a steady recovery by the life sciences industry, it looks like 2025 is set to be a year of change and ...

Antibody drugs have reshaped how we treat diseases. By harnessing the immune system to destroy tumours or temper excessive inflammation in autoimmune disorders, these therapeutics have become ...